Licensed Practical Nurse in Morganton, NC Accepting Medicare
4 Licensed Practical Nurse nurses found. Showing 1 - 4
 Thomas Jay Sciarra Jr., Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 129 Clearwater Dr, Morganton, NC 28655 Phone: 828-334-2937 |
 Katherine Crawford, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 301 E Meeting St Ste 11, Morganton, NC 28655 Phone: 828-655-3243 |
Mr. Jeffrey Griffiths, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 301 E Meeting St Ste 11, Morganton, NC 28655 Phone: 828-655-3134 |
Melissa Roll, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 301 E Meeting St, Morganton, NC 28655 Phone: 828-659-3418 |
News Archive
Nose cells provide a window into the brain
In the first study to examine living nerve cells from patients with psychiatric disease, scientists from the Monell Chemical Senses Center, the University of Pennsylvania, and collaborating institutions report altered nerve cell function in olfactory receptor neurons from patients with bipolar disorder.
genOway to provide EUCOMM conditional knockout mouse models to study human diseases
genOway, the biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum München (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) announce today the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM.
Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA
A new study presented for the first time today at the European League Against Rheumatism Annual Congress (EULAR 2014), shows that cranial ultrasound has a greater sensitivity than temporal artery biopsy,* and a comparable specificity in the diagnosis of Giant Cell Arteritis (GCA).
Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.
Genentech uses Complete Genomics' sequencing service to compare primary lung tumor, adjacent normal tissue
Complete Genomics Inc., a third-generation human genome sequencing company, today announced that Genentech Inc., a wholly owned member of the Roche Group, used the company's sequencing, bioinformatics and analytics services to sequence and compare a patient's primary lung tumor and adjacent normal tissue.
› Verified 7 days ago